Our Mission

Dikran Tourian is Founder and CEO of Biozen and an entrepreneur, investor and medical technology executive with more than 25 years of experience building and scaling companies across healthcare, technology and energy. His ventures include PrimaTech Medical Systems, which was acquired by Anodyne Medical Device, and Signature Investments, an Oklahoma City-based private investment firm where he serves as Founder and CEO. Tourian attended the University of Oklahoma’s Price College of Business and has served as a Chapter Membership Chair for YPO.

Omer Inan, PhD, is Biozen’s Chief Scientific Officer and an internationally recognized scientist and engineer specializing in wearable medical devices, physiological sensing and cardiovascular monitoring. He is the Linda J. and Mark C. Smith Chair and Professor of Electrical and Computer Engineering at Georgia Tech. A Stanford-trained electrical engineer and Fellow of both IEEE and AIMBE, his research has advanced wearable technologies for noninvasive cardiovascular assessment and monitoring.

Javier Benson-Glanz serves as Chief Financial Officer at Biozen and is an entrepreneur and business leader with experience spanning strategy, operations, finance and technology-driven businesses. He is Co-Founder and Managing Partner of enable.inc and has held leadership roles across operations, growth and product strategy. A graduate of the University of Pennsylvania and The Wharton School, his background combines engineering, finance and business strategy with experience building and scaling companies.

Shaun Dubuque is Biozen’s Chief Technology Officer and an engineer with expertise spanning software architecture, AI, signal processing and embedded systems. A University of Texas at Austin-trained electrical engineer, his career spans research, consumer technology, healthcare and cybersecurity, and includes five U.S. patents. At Biozen, he leads the technology stack supporting the company’s blood pressure platform from development through production and integration.

Goktug Ozmen, PhD, is Biozen’s Vice President of Research and Development and an engineer and researcher specializing in wearable sensing, physiological signal processing and machine learning. A Georgia Tech-trained researcher, his work has focused on extracting meaningful physiological information from novel biosignals and wearable technologies. Ozmen has helped advance the company’s blood pressure technology from research and development through clinical validation, manufacturing and FDA clearance.

Michael Chan, PhD, is Biozen’s Principal Machine Learning Architect specializing in machine learning and computational analysis of physiological signals. A Georgia Tech-trained researcher, his work focuses on using advanced computational methods to extract clinically meaningful cardiovascular information from complex biosignals. At Biozen, he contributes to the algorithms, clinical research and published science underlying the company’s blood pressure measurement technology.

Erno Klaassen, PhD, is a member of Biozen’s Advisory Board and a technology and medical-device executive with deep expertise in cardiovascular sensing, wearable health and consumer health technology. He spent more than 12 years as Senior Director of Health Technologies at Apple during the evolution of Apple Watch health capabilities. A named inventor on patents spanning cardiovascular sensing and blood pressure measurement, his career combines medical-device engineering with experience developing health technologies for consumer wearables.

Hooi Tan is a member of Biozen’s Advisory Board and a global operations executive with decades of experience scaling complex technologies through manufacturing and supply-chain organizations. He is Chief Operating Officer of Flex, overseeing global manufacturing, procurement, supply chain, operational excellence and quality. During more than two decades at Flex, he has held senior global leadership roles, including responsibility for more than 100 facilities across 30 countries.

Scott Mueller is a member of Biozen’s Advisory Board and an investment and finance executive with extensive experience in private equity, wealth management and corporate finance. He is a Managing Director and Regional Head of the Southwest Region for Private Wealth Management at Goldman Sachs, where he began his career in 1999. His career also includes senior leadership roles in private equity and corporate finance, as well as service as Oklahoma’s Secretary of Commerce and Workforce Development.

Bruce C. Friedman, PhD, is a member of Biozen’s Advisory Board and a medical instrumentation and blood pressure measurement specialist with decades of experience in noninvasive monitoring technology. During his career with GE Healthcare, his work included the development and evaluation of noninvasive blood pressure algorithms, including GE’s DINAMAP technology. He has published research on blood pressure measurement and contributed to international standards for evaluating noninvasive blood pressure devices.

Alta Schutte, PhD, is a member of Biozen’s Advisory Board and an internationally recognized authority on hypertension, blood pressure and cardiovascular health. She is a SHARP Professor at UNSW Sydney and Global Co-Director of the Cardiovascular Program at The George Institute for Global Health. A past President of the International Society of Hypertension and author of more than 550 scientific publications, she has helped shape international hypertension research, guidelines and global initiatives.

Ranndy Kellogg is a member of Biozen’s Advisory Board and a healthcare executive with decades of leadership in cardiovascular technology, blood pressure monitoring and digital health. He served as President and CEO of OMRON Healthcare North America, leading the organization during a period of significant advancement in connected blood pressure monitoring, digital health and remote patient monitoring. His career has centered on bringing cardiovascular technologies to broad consumer and clinical markets.

Rick Nagel is a member of Biozen’s Advisory Board and a private equity and strategic investment executive with more than 25 years of experience investing in and scaling technology-driven companies. He is Managing Partner and CEO of Acorn Capital Management and currently serves as Chair of the University of Oklahoma Board of Regents. A University of Oklahoma engineering graduate, his career spans investment strategy, capital formation and growth across highly technical industries.

Jay Shah, MD, FACC, is a Medical Advisor to Biozen and a cardiologist and healthcare executive with more than 15 years of experience spanning clinical medicine, cardiovascular technology and healthcare leadership. He trained at Massachusetts General Hospital and Washington University in St. Louis and later helped develop cardiovascular programs at Mayo Clinic. He also served as Chief Medical Officer of Aktiia, bringing direct experience in cuffless blood pressure technology and medical-device innovation.

Kenneth Civello, MD, MPH, is a Medical Advisor to Biozen and a cardiologist and cardiac electrophysiologist with expertise spanning cardiovascular medicine, artificial intelligence, remote monitoring and wearable technology. Board certified in internal medicine, cardiovascular disease and cardiac electrophysiology, he is Co-Founder of Suture Health and a practicing electrophysiologist. His work explores how physiological data and emerging technologies can extend cardiovascular insight beyond traditional clinical settings.

Seth Bilazarian, MD, is a Medical Advisor to Biozen and a clinical and interventional cardiologist with decades of experience spanning cardiovascular medicine, clinical research and medical-device innovation. After more than two decades in clinical practice, he joined Abiomed, where his leadership has included clinical research, physician education and the development and adoption of Impella heart-support technologies. His career bridges frontline cardiovascular medicine and advanced cardiac-device development.

George Chrysant, MD, is a Medical Advisor to Biozen and an interventional cardiologist with extensive experience in cardiovascular medicine, clinical research and advanced cardiac imaging. He serves as Chief Scientific Officer and Chairman of the Department of Cardiology at INTEGRIS Health and as Director of Cardiac Imaging. His expertise spans interventional cardiology, structural heart disease, vascular intervention and advanced cardiovascular imaging.

Dikran Tourian is Founder and CEO of Biozen and an entrepreneur, investor and medical technology executive with more than 25 years of experience building and scaling companies across healthcare, technology and energy. His ventures include PrimaTech Medical Systems, which was acquired by Anodyne Medical Device, and Signature Investments, an Oklahoma City-based private investment firm where he serves as Founder and CEO. Tourian attended the University of Oklahoma’s Price College of Business and has served as a Chapter Membership Chair for YPO.

Aamir Mahmood serves on Biozen’s Board of Directors and is a medical device executive with more than two decades of leadership experience in global cardiovascular markets. He is President and CEO of Acarix, a publicly listed cardiovascular diagnostics company, and previously served as General Manager and Vice President, Americas, for MicroPort CRM. His career also includes global leadership roles spanning sales, marketing, strategy and M&A at LivaNova, Boston Scientific and Merck.

David LaLonde serves on Biozen’s Board of Directors and is a finance executive with more than two decades of experience in private equity, investment banking and corporate leadership. As CFO of Black Swan Oil & Gas, he played a central role in the acquisition, development and financing of its Midland Basin assets, which were ultimately sold to Ovintiv in a transaction valued at approximately $2 billion. He holds an MBA from The Wharton School and degrees in accounting and finance from Texas A&M University.

Erich M. Platzer, MD, PhD, serves on Biozen’s Board of Directors and is a physician, scientist, life sciences executive and healthcare investor with decades of experience across medicine, pharmaceutical development and biotechnology. He held senior oncology leadership roles at Roche and co-founded HBM Healthcare Investments. Earlier in his career, he was part of the Memorial Sloan Kettering Cancer Center team that purified human G-CSF, later developed as Neupogen, and has served on numerous biotechnology company boards.